Leander Merritt
Eli Lilly and Company
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Leander Merritt.
Bioorganic & Medicinal Chemistry Letters | 1994
John S. Ward; Leander Merritt; Frank P. Bymaster; David O. Calligaro
Abstract Isoarecolones and arecolones bearing different ketone substituents were synthesized and their affinities at central muscarinic and nicotinic receptors determined. The compounds were selective for nicotinic receptors, produced appropriate nicotinic responses, and crossed the blood brain barrier in rats.
Biochemical and Biophysical Research Communications | 1992
Dan O. Ngur; Scott Roknich; Charles H. Mitch; Steven J. Quimby; John S. Ward; Leander Merritt; Per Sauerberg; William S. Messer; Wayne Hoss
A series of arecoline derivatives was utilized to assess steric and electronic effects important for activating muscarinic receptors in the CNS. Arecoline derivatives in which the methyl ester moiety was replaced by hexyloxy-1,2,5-oxadiazole (2b), hexyloxythiophene (3b) or hexyloxypyrazine (4b) were compared with the hexyloxy-1,2,5-thiadiazole compound (1b) (Hexyloxy-TZTP), known from previous work to be active as an M1/M3 partial agonist. MNDO calculations showed that the N-S bonds of the alkoxythiadiazole ring were highly polarized with the ability to form H-bonds to the Ns. On the other hand, the smaller oxadiazole had lower polarities in the N-O bonds and reduced ability to form H-bonds, the thiophene was of comparable size to the thiadiazole and had large C-S bond polarities without the H-bond capability and the pyrazine had limited ability to form H-bonds. The compounds were compared with respect to their abilities to stimulate phosphoinositide (Pl) turnover in the hippocampus of the rat brain. 1b was more active than 2b-4b for stimulating the Pl turnover response. The data suggest that the ability to form H-bonds is an important factor for the ability of 1 to stimulate M1 muscarinic receptors in the CNS.
Journal of Medicinal Chemistry | 1992
John S. Ward; Leander Merritt; Valentine J. Klimkowski; Michelle L. Lamb; Charles H. Mitch; Franklin Porter Bymaster; Barry D. Sawyer; Harlan E. Shannon; P. Olesen; Honoré T
Journal of Medicinal Chemistry | 1998
John S. Ward; Leander Merritt; David O. Calligaro; Franklin Porter Bymaster; Harlan E. Shannon; Charles H. Mitch; Celia A. Whitesitt; David Brunsting; Malcolm J. Sheardown; Preben H. Olesen; Michael D. B. Swedberg; Lone Jeppesen; Per Sauerberg
Journal of Medicinal Chemistry | 1995
J.S. Ward; Leander Merritt; David O. Calligaro; Franklin Porter Bymaster; Harlan E. Shannon; Barry D. Sawyer; C.H. Mitch; Deeter Jb; Steven C. Peters; Malcolm J. Sheardown; Preben H. Olesen; Swedberg; Per Sauerberg
Journal of Heterocyclic Chemistry | 1991
John S. Ward; Leander Merritt
Archive | 1998
Leander Merritt; John S. Ward
Journal of Heterocyclic Chemistry | 1990
John S. Ward; Leander Merritt
Journal of Medicinal Chemistry | 1988
John S. Ward; Ray W. Fuller; Leander Merritt; Harold D. Snoddy; Jonathan W. Paschal; Norman R. Mason; J. S. Horng
Archive | 1987
Leander Merritt; John S. Ward